




A Immune signature




B T cell inflamed signature



C T cell inflamed signature



D Cytotoxic signature



E Cytotoxic signature




Fig. S13. Kaplan–Meier plots showing progression-free survival and overall survival differences for patients receiving anti-PD1 between the low-risk and high-risk groups defined by the median value of deepBTAS. The analysis done separately on tumors with high (right) and low (left) levels of biomarker. Analysis done for Immune (A), T cell inflamed (B-C), and Cytotoxic signature (D-E).